PG-102(MG12)

DRUG2 trials

Sponsors

ProGen. Co., Ltd.

Conditions

HealthyOverweightType 2 Diabetes

Phase 1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.

CompletedNCT06309667

ProGen. Co., Ltd.Healthy, Overweight

Start: 2024-03-04End: 2025-02-05Updated: 2025-05-06

Phase 2

Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus

Not yet recruitingNCT07677891

ProGen. Co., Ltd.Type 2 Diabetes

Start: 2026-10-01End: 2027-06-01Target: 60Updated: 2026-07-01

Related Papers

Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial

Nature Communications2026-03-24